Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | TSC1 loss |
| Gene Variant Detail | |
| Relevant Treatment Approaches | mTOR Inhibitor mTORC1 Inhibitor |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| TSC1 loss | urinary bladder cancer | sensitive | mTORC1 Inhibitor | Sirolimus | Preclinical | Actionable | In a preclinical study, Rapamune (sirolimus) inhibited proliferation of cultured bladder cancer cells lacking TSC1 (PMID: 23401075). | 23401075 |
| TSC1 loss | urinary bladder cancer | sensitive | mTOR Inhibitor | Torin 1 | Preclinical | Actionable | In a preclinical study, Torin 1 inhibited proliferation of cultured bladder cancer cells lacking TSC1 (PMID: 23401075). | 23401075 |
| TSC1 loss | urinary bladder cancer | sensitive | mTORC1 Inhibitor | Luminespib + Sirolimus | Preclinical | Actionable | In a preclinical study, Luminespib (AUY922), in combination with Rapamune (sirolimus), inhibited growth of bladder cancer cells lacking TSC1 to a greater extent than either therapy alone (PMID: 23401075). | 23401075 |
| TSC1 loss | urinary bladder cancer | sensitive | mTOR Inhibitor | Luminespib + Torin 1 | Preclinical | Actionable | In a preclinical study, Luminespib (AUY922), in combination with Torin 1 inhibited growth of bladder cancer cells lacking TSC1 to a greater extent than either therapy alone (PMID: 23401075). | 23401075 |